The Cowden+ Support Program: A Comprehensive Guide to Herbal-Based Lyme Disease Management
INTEGRATIVE INFECTIOUS DISEASE
Yoon Hang Kim, MD, MPH
Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician
Dr. Yoon Hang Kim is board-certified in Preventive Medicine and practices integrative & functional medicine. He completed the University of Arizona Center for Integrative Medicine Osher Fellowship under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture, and integrative and functional medicine. He is an IFM Scholar with over 20 years of clinical experience. Dr. Kim specializes in low dose naltrexone (LDN), autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome, and mold toxicity. He is the author of 8 books — including MCAS: Epidemic in Plain Sight and LDN Primer — and has published more than 25 peer-reviewed articles. He is the founder of the LDN Support Group.
Professional: www.yoonhangkim.com | Clinical: www.directintegrativecare.com
Important: This article is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Lyme disease and tick-borne co-infections require individualized evaluation by qualified clinicians. Herbal protocols should be undertaken under clinical supervision. If you experience signs of a severe Jarisch-Herxheimer reaction, anaphylaxis, or neurological deterioration, seek emergency medical care immediately. Always consult your own physician before making changes to your treatment plan.
The Cowden+ Support Program: A Comprehensive Guide to Herbal-Based Lyme Disease Management
Summary Table
Element | Detail |
What it is | A structured, 6-month rotational herbal and botanical regimen for chronic Lyme disease and co-infections |
Developer | Lee Cowden, MD; now marketed by Nutramedix as the Cowden+ Support Program |
Core strategy | Monthly rotation of three proprietary herbal blends (Nutra-BRL → Nutra-BRT → Nutra-BBS+) with biofilm-disrupting enzymes and detoxification support |
Duration | 6 months initial; Months 4–6 repeatable as needed |
Strongest evidence | Component-level and in vitro: University of New Haven and Johns Hopkins studies show Samento, Banderol, and Artemisia annua active against B. burgdorferi morphological forms [5][8]; Stevia evidence is discordant across labs |
Evidence limitations | No prospective randomized trials of the complete protocol in humans; clinical data is observational and practitioner-reported |
Key safety concern | Distinct transporter/enzyme effects: Banderol inhibits hepatic uptake transporters OATP1B1/OATP1B3; Samento activates PXR and induces ABCB1/P-glycoprotein and CYP3A4 effects. Clinical magnitude unestablished — reconcile medications [9] |
Approximate cost | USD $250–$350/month; $1,500–$2,100 for full 6-month program |
Best candidates | Clients with antibiotic failure, antibiotic intolerance, seronegative Lyme-like syndrome, or significant co-infections |
What Is the Cowden+ Support Program?
The Cowden Support Program, now marketed as the Cowden+ Support Program by Nutramedix, is a structured, six-month herbal and botanical regimen designed to support clients with chronic Lyme disease, co-infections, and related complex chronic illnesses. Developed by Lee Cowden, MD, the protocol employs a rotational approach using proprietary herbal blends, biofilm-support enzymes, and detoxification support to address microbial challenges, inflammatory responses, and Herxheimer-like reaction management [1]. This document provides an overview of the protocol's components, clinical rationale, practical implementation, and evidence base for healthcare providers and informed clients.
How Did the Cowden Protocol Develop?
The Cowden Protocol emerged from clinical experience treating clients with documented or suspected Borrelia burgdorferi (Lyme) infections who either declined antibiotic therapy, experienced antibiotic resistance or intolerance, or had persistent symptoms after conventional treatment [1]. Dr. Lee Cowden and collaborators described observational data from a 2003 Dallas cohort reporting symptomatic improvement in Lyme clients treated with the herbal support approach [1]. The protocol gained adoption among integrative and functional medicine practitioners, particularly those treating Lyme-complex cases empirically — that is, clinical presentations consistent with Lyme even when serology is negative or indeterminate.
The program was recently revised and rebranded as Cowden+ Support Program, featuring streamlined dosing (twice-daily rather than multiple daily doses), enhanced proprietary blended formulas to simplify adherence, and updated supporting materials [2]. Despite updates in packaging and delivery, the core mechanistic approach remains consistent.
A note on evidence level: The 2003 Dallas cohort is not available as a peer-reviewed primary publication, and this article does not present it as a formal study. The most traceable clinical observation comes from Richard Horowitz, MD, a founding ILADS member, who presented his experience using the Cowden Support Program in a group of Lyme and co-infection clients at the 2007 ILADS Annual Conference and later described it in his 2013 book Why Can't I Get Better? He reported that roughly two-thirds to three-quarters of clients improved on full or modified Cowden strategies (used with or without antibiotics), and he observed relapse when the protocol was used for less than six months. Critically, Horowitz himself concluded that controlled trials were needed to determine which herbal combinations are safest and most effective. This is uncontrolled clinical observation, not randomized trial data, and insufficient methodological detail is available to estimate a treatment effect reliably. A separate nine-month observational evaluation was later conducted in Augsburg, Germany. Both represent practitioner and observational experience.
Why a Functional-Medicine Model Fits Better Than "Bug in a Biofilm"
Before detailing the protocol, it helps to frame why an integrative, multi-targeted botanical strategy is philosophically coherent — and here the functional-medicine model has grown considerably more sophisticated than a simple "persistent hidden infection" narrative.
Emerging biology supports a host-response model of persistent post-Lyme symptoms rather than attributing everything to viable organisms hiding in biofilm. In treated Lyme neuroborreliosis, persistent symptoms have been associated with sustained systemic interferon-α even after cerebrospinal-fluid inflammation resolved [15]. Metabolomic work has identified differences in glycerophospholipids, bile acids, and acylcarnitines between clients with post-treatment Lyme disease symptoms and recovered controls [16]. This fits Richard Horowitz's Multiple Systemic Infectious Disease Syndrome (MSIDS) framework, which treats persistent illness as multifactorial — infection, immune dysregulation, inflammation, gastrointestinal factors, environmental exposures, nutritional abnormalities, sleep, autonomic and mitochondrial dysfunction, and other contributors — rather than reducing it to a single cause [22]. Notably, even the 2025 National Academies report on Lyme infection-associated chronic illnesses has moved toward this broader model, explicitly weighing pathogen/antigen persistence, autoimmunity, immune dysregulation, and microbiome alterations rather than treating the biology as settled [17].
The clinical takeaway: a strategy that simultaneously applies botanical antimicrobial pressure and addresses host resilience, inflammation, detoxification capacity, and coexisting conditions is conceptually aligned with where the science is actually heading — a model in which persistent viable infection is one possible mechanism among several, not the only permissible explanation.
Where the Cowden Protocol Sits Relative to ILADS
The 2014 ILADS guideline is philosophically relevant to this protocol, though it is important to be precise: ILADS emphasizes individualized assessment, clinical judgment, reassessment of the original diagnosis, evaluation for coinfections and alternative causes of persistent symptoms, patient preferences, and individualized therapeutic trials rather than a rigid one-size-fits-all approach [18]. ILADS does not specifically endorse or validate the Cowden herbal protocol — its persistent-disease recommendations primarily address antibiotic retreatment, and ILADS grades much of that evidence as low quality. The accurate framing is therefore that the Cowden Protocol is compatible with the individualized, shared-decision-making philosophy used by many ILADS-oriented clinicians, not that it is "supported by ILADS."
What Is the Core Philosophy and Mechanism?
The Cowden Protocol operates on several integrated principles:
Rotational Antimicrobial Targeting
Rather than a single antimicrobial agent, the protocol rotates through three distinct herbal blends over a six-month cycle, each with slightly different microbial targets. On the working hypothesis (plausible but not established specifically for the Cowden Protocol), this approach aims to:
Reduce adaptive resistance by the target organisms
Address polymicrobial communities (Lyme commonly co-exists with Babesia, Ehrlichia, Bartonella, and others)
Minimize Herxheimer reactions by pulsing rather than sustaining single-agent therapy
Improve long-term tolerability through chemical diversity
Biofilm Disruption
Proteolytic enzymes (bromelain and serrapeptase) are incorporated on the hypothesis that degradation of fibrinous or proteinaceous extracellular matrices may improve antimicrobial access to organisms sheltered within biofilm. Sapi et al. (2012) demonstrated that Borrelia burgdorferi can form organized aggregates with extracellular polymeric matrix characteristics consistent with biofilm in vitro [3], which is genuine mechanistic evidence that the target exists. Bromelain also has human anti-inflammatory and pharmacologic literature [19], and bromelain-based enzymatic debridement has shown effects on biofilm-containing chronic wounds in human studies [20]. However, this is mechanistically plausible extrapolation, not established fact: no human study has demonstrated that orally administered bromelain or serrapeptase disrupts Borrelia biofilm in vivo. The rationale is retained here as a working hypothesis, correctly leveled.
Drainage Support and Flare Tolerability
The protocol incorporates drainage-supporting botanicals (burbur-pinella, dandelion) intended to support elimination pathways during treatment-associated symptom flares. This use derives primarily from traditional and clinical practice rather than controlled studies demonstrating accelerated toxin clearance or prevention of Jarisch-Herxheimer reactions. The staged, "go-low-and-slow" design is central to the protocol's tolerability philosophy, on the clinical reasoning that rapid microbial die-off without supportive drainage may provoke treatment-limiting flares.
Nutritional and Energetic Support
Magnesium malate is included for muscle pain, fatigue, and ATP production support — addressing a common Lyme symptom cluster. This reflects understanding that chronic Lyme is not purely an antimicrobial challenge but a multi-system inflammatory and energetic dysfunction [14].
What Does the Six-Month Program Look Like?
Month 1: Embarking on Microbial Support
Dosing Philosophy: Low starting dose, gradual titration upward over 2–4 weeks to minimize Herxheimer reactions in newly treated clients.
Primary Products:
Nutra-BRL (contains Stevia, Samento [Cat's Claw TOA-free], and Banderol): Broad-spectrum microbial and inflammatory support
Takuna: Traditional Amazonian plant used historically for inflammation and immune modulation
Bromelain and Serrapeptase: Proteolytic enzymes targeting biofilm matrix
Burbur-Pinella: Herbal drainage/support formula; practitioner-directed, particularly during treatment-associated symptom flares
Dandelion (root/leaf extract): Liver and lymph drainage; diuretic properties support elimination pathways
Magnesium Malate: 2:1 complex (magnesium and malic acid) for muscle pain, mitochondrial support, and fatigue
Clinical Goal: Establish tolerability and baseline, begin gentle microbial pressure, support elimination pathways.
Month 2: Rotation to New Antimicrobial Blend
Dosing Philosophy: Reset to low dose again despite prior month's tolerance, as this introduces a new herbal combination with different target organisms.
Primary Products:
Nutra-BRT (contains Cumanda and Houttuynia): Different botanical targets than Nutra-BRL; Houttuynia is a traditional antimicrobial from East Asian herbalism
GlucoMedix (contains Stevia and Samento): Provides continued Samento exposure at lower concentration alongside new blend
Takuna, Bromelain, Serrapeptase, Burbur-Pinella, Dandelion, Magnesium Malate: Continued support as in Month 1
Clinical Goal: Introduce new microbial pressure vector; monitor for different Herxheimer profile.
Month 3: Introduction of Botanical Combination
Dosing Philosophy: Low start with new blend; this month introduces the most complex herbal formula in the 6-month cycle.
Primary Products:
Nutra-BBS+ (contains Elecampane, Jalap, Artemisia annua, and Capirona): Traditional anti-parasitic and antimicrobial herbs; Artemisia annua (sweet wormwood) has documented in vitro activity against various pathogens including B. burgdorferi stationary phase forms [8]
GlucoMedix: Continued as in Month 2
Takuna, Bromelain, Serrapeptase, Burbur-Pinella, Dandelion, Magnesium Malate: Continued support
Clinical Goal: Introduce botanicals with anti-parasitic profile; support for Babesia and other co-infections. Recommendation is to continue 2 months past subjective "feeling well" to address persistent organisms.
Months 4, 5, 6: Intensified Dosing with Repeated Blends
Dosing Philosophy: Return to Month 1–3 herbal combinations but at higher, established doses to maximize microbial support after baseline has been established.
Month 4: Nutra-BRL (full dose)
Month 5: Nutra-BRT (full dose)
Month 6: Nutra-BBS+ (full dose)
Plus supportive products at maintained doses: Bromelain, Serrapeptase, Burbur-Pinella, Dandelion, Magnesium Malate.
Clinical Goal: Consolidate gains from Months 1–3 with higher-intensity therapy; repeat Months 4–6 as needed until symptom stabilization achieved.
What Are the Key Active Herbal Components?
Samento (Cat's Claw, Uncaria tomentosa)
Traditional use: Immune support, anti-inflammatory, antimicrobial (Peruvian traditional medicine)
Botanical mechanism: Pentacyclic oxindole alkaloids (TOAs reduced in Samento formulation) may modulate NF-κB signaling and support immune regulation [4]
Applied use in protocol: Broad-spectrum microbial activity including against spirochetes; used in both Nutra-BRL and GlucoMedix formulas
In vitro evidence: In the Datar/Sapi (2010) Townsend Letter work, Samento was active against all B. burgdorferi morphological forms — spirochetes, round bodies, and biofilm-like colonies — outperforming doxycycline against non-spirochetal forms, especially combined with Banderol [5]. Separately, the Feng/Zhang (2020) Johns Hopkins screen found Uncaria tomentosa active against stationary-phase B. burgdorferi — independent support for this botanical, though that study tested the herb, not the Cowden product or protocol [8].
Safety data: Weiss (2019) found Samento weakly inhibits CYP3A4 (~40% at 1%) and, via PXR activation, induces ABCB1/P-glycoprotein and related genes — an induction profile, not simple inhibition. This differs entirely from Banderol's profile (OATP1B1/1B3 inhibition). Reconcile medications; clinical magnitude at human doses is unestablished [9].
Clinical note: Some practitioners titrate carefully due to immune-stimulating potential; clients with autoimmune conditions may require monitoring.
Banderol (Otoba parvifolia)
Traditional use: Amazonian antimicrobial; traditional use for infections
Botanical mechanism: Benzofuran and phenolic compounds with antimicrobial activity
Applied use in protocol: Often selected for spirochete and co-infection coverage; combined with Samento for synergy
In vitro evidence: More effective in combination with Samento than either agent alone against all three B. burgdorferi morphological forms [5]. Pharmacokinetic interaction profile characterized by Weiss (2019) [9].
Clinical note: Less studied than Samento in peer-reviewed literature; inclusion reflects practitioner experience and traditional Amazonian ethnobotany.
Cumanda (Himatanthus sucuuba)
Traditional use: South American rainforest plant used for various infections
Botanical mechanism: Understudied in Western literature; traditional use suggests anti-inflammatory and antimicrobial properties
Applied use in protocol: Represents new microbial target in Month 2 rotation
Clinical note: Limited peer-reviewed data; inclusion is empirical based on clinical experience. Sapi's expanded in vitro evaluations (presented at national Lyme conferences 2013 and 2015) tested Cumanda among other Cowden Protocol herbs against three forms of B. burgdorferi [6].
Houttuynia (Houttuynia cordata)
Traditional use: East Asian ethnomedicine (Japan, Vietnam, China); used for respiratory and urinary tract infections
Botanical mechanism: Volatile oils and polyphenols with demonstrated antimicrobial activity against various bacteria and viruses [10]
Applied use in protocol: Provides different microbial pressure than Samento/Banderol; often selected for persistent respiratory or CNS-related Lyme symptoms
Clinical note: Some in vitro data supporting antimicrobial activity; clinical translation to Lyme disease is primarily practitioner-based.
Artemisia annua (Sweet Wormwood)
Traditional use: Traditional Chinese medicine for febrile illnesses; artemisinin derivatives are established antimalarial agents
Botanical mechanism: Artemisinin and sesquiterpene lactones; well-documented antimicrobial and antiparasitic activity
Applied use in protocol: Specifically included for parasitic co-infections (particularly Babesia), reflecting mechanism-based rationale
In vitro evidence: Ranked among the seven most active botanical agents against stationary phase B. burgdorferi in the Feng et al. (2020) Johns Hopkins study [8]. Artemisinin derivatives have an established clinical track record as antimalarials.
Clinical note: Inclusion in Month 3 supports antiparasitic intentions, particularly for Babesia co-infection.
Stevia (Stevia rebaudiana)
Applied use in protocol: Included in Nutra-BRL and GlucoMedix blends; often highlighted for anti-biofilm activity.
In vitro evidence — and an important caveat: The laboratory evidence for Stevia is discordant, and this is a useful pharmacognosy teaching point. Theophilus et al. (2015) reported that a particular whole-leaf Stevia extract had significant activity against multiple B. burgdorferi morphological forms, including biofilm [7]. However, the later Feng et al. (2020) Johns Hopkins botanical screen did not reproduce comparably impressive activity for Stevia under its stationary-phase assay conditions [8]. Differences in extraction method, preparation, concentration, organism state, and assay design likely account for the discordance. The clinical lesson: "Stevia" is not a chemically uniform intervention. Different extracts cannot be treated as interchangeable, and product formulation, dose, and preparation matter — a point emphasized in the 2023 comprehensive review of herbal supplements used for persistent Lyme symptoms [21].
Bromelain (Pineapple Enzyme)
Mechanism: Serine protease; degrades fibrin and extracellular matrix proteins
Applied use: Biofilm-disruption support; anti-inflammatory properties via suppression of cytokine release
Evidence base: Rationale supported by Sapi et al. (2012) confirmation of true B. burgdorferi biofilm formation [3]. Direct clinical evidence for bromelain-mediated biofilm disruption in Lyme specifically remains preclinical.
Serrapeptase (Serratia peptidase)
Mechanism: Serine protease from Serratia marcescens; cleaves non-collagen proteins
Applied use: Similar to bromelain — biofilm matrix degradation and inflammatory modulation
Evidence base: Laboratory evidence for biofilm disruption; less extensive clinical trial data than bromelain, but combined use is common in integrative practice.
Burbur-Pinella
Composition: Proprietary blend (exact constituents vary by manufacturer) traditionally combining Burbur (Desmodium species) and Pinella
Mechanism: Used within the Cowden system as a practitioner-directed drainage/support formula. Note: this is not a "binder" in the physicochemical sense — activated charcoal and certain clays adsorb and bind toxins, whereas an herbal drainage tincture is conceptually different and lacks adsorption/binding data
Applied use: Positioned for use during treatment-associated symptom flares; often described as "rescue" dosing when reactions intensify
Clinical note: Central to the protocol's tolerability philosophy, but its use derives from traditional and clinical practice rather than controlled studies demonstrating accelerated toxin clearance or prevention of Jarisch-Herxheimer reactions.
Dandelion (Taraxacum officinale)
Mechanism: Diuretic; bitter compound stimulation of bile; mineral-rich (potassium, calcium)
Applied use: Hepatic and renal clearance support; addresses mineral depletion from chronic illness and increased elimination demands
Evidence base: Long traditional use with limited high-quality clinical trials; supportive evidence for hepatic function and mineral status [11].
Magnesium Malate (Mg-Malate Complex)
Mechanism: Magnesium is a cofactor in >300 enzymatic reactions; malic acid is involved in the Krebs cycle; combination supports mitochondrial ATP production
Applied use: Specifically targets Lyme-associated muscle pain, fatigue, and energetic dysfunction
Evidence base: Magnesium deficiency is common in chronic illness states; the malate form has evidence supporting its use in fibromyalgia-spectrum pain conditions [14]. The combined inclusion rationale is physiologically sound.
What Are the Clinical Implementation Considerations?
Client Selection and Screening
The Cowden Protocol is typically offered to clients with:
Documented Lyme disease (positive 2-tier serology) with persistent symptoms despite antibiotics
Seronegative Lyme-like syndrome (clinical Lyme presentation without seroconversion)
Lyme with significant co-infections (Babesia, Bartonella, Ehrlichia)
Inability or unwillingness to tolerate conventional antibiotic therapy (allergy, GI intolerance, or prior adverse response)
Previous antibiotic therapy with inadequate response
Cautions and contraindications:
Significant hepatic dysfunction (high herbal load); requires case-by-case evaluation
Severe immunocompromise (may require modified dosing; some practitioners advise caution with immune-stimulating herbs like Samento)
Concurrent antibiotic or antimicrobial therapy: often combined intentionally, but requires coordinated monitoring. Weiss (2019) found distinct in vitro transporter/enzyme effects — Banderol inhibits hepatic uptake transporters OATP1B1/OATP1B3, while Samento activates PXR and induces ABCB1/P-glycoprotein along with CYP3A4 effects; reconcile medications, especially those with narrow therapeutic indices or transporter-dependent disposition [9]
Pregnancy and lactation: human reproductive-safety data for these multi-herbal formulations are inadequate. Pregnancy and lactation require separate, ingredient-by-ingredient risk assessment; the complete Cowden Protocol has not been adequately studied in this population
Treatment-Emergent Flares: Not Always "Die-Off"
Treatment-emergent flaring is commonly reported clinically with the Cowden Protocol, and slow titration is a reasonable tolerability strategy. However, an important caution: Cowden-specific prospective data establishing the incidence, onset, duration, severity, or predictive value of these reactions do not exist. This section should be read as clinical-practice guidance, not as a prospectively validated trajectory.
More importantly, a symptom flare should not automatically be interpreted as microbial die-off. The differential is broad and clinically consequential:
Direct botanical intolerance
Mast-cell / histamine activation (particularly important in MCAS-prone clients)
Drug or herb-drug interaction
Gastrointestinal intolerance
Hepatic adverse effect
Allergy
Underlying disease fluctuation
Unrelated intercurrent illness
Reflexively labeling every flare a "Herxheimer reaction" risks missing an adverse drug effect, an allergy, or a mast-cell event that warrants a different response. This distinction matters especially in clients with known or suspected mast cell activation syndrome, in whom botanical exposures can provoke mediator release that mimics — but is mechanistically distinct from — a die-off reaction.
Tolerability strategies commonly used:
Low initial dosing with slow titration
Reset to low dose when introducing new blends
Concurrent drainage-support botanicals from the outset
Client education on the reaction spectrum and, critically, on the difference between a tolerability flare and a true adverse reaction that requires stopping
When a flare occurs:
Reassess the differential above before assuming die-off
Reduce antimicrobial product doses temporarily
Supportive care (rest, hydration, sleep)
Increase drainage-support botanicals as practitioner-directed (traditional/clinical rationale, not proven to prevent Jarisch-Herxheimer reactions)
Discontinue and reassess if the reaction is severe, allergic, or suggests hepatic injury
How Does the Cowden Protocol Integrate with Other Therapies?
With Antibiotics
Some clinicians use the Cowden Protocol concurrently with antibiotics during specific phases, reasoning that multi-targeted therapy may improve outcomes. This is individualized and requires close monitoring. The protocol was originally designed as an alternative to antibiotics, but combination use is increasingly discussed in integrated practice. Sapi et al. (2011) demonstrated that different antibiotics have variable effectiveness against different morphological forms of B. burgdorferi — doxycycline was effective against spirochetes but not against round bodies or biofilm colonies — providing mechanistic rationale for combination approaches [6].
With LDN (Low-Dose Naltrexone)
LDN is used off-label in Lyme to reduce inflammation and modulate immune response. Many practitioners combine LDN (titrated separately) with the Cowden Protocol, though no formal evidence exists on drug-herb interactions. The combination is generally regarded as synergistic for anti-inflammatory effect but requires coordination of timing and monitoring. For more on LDN, see the LDN Primer and the LDN articles on ifmsynergy.com.
With Other Supplements
Practitioners often layer in:
Probiotics and prebiotic fiber: Support microbiome restoration post-die-off
Omega-3 fatty acids: Anti-inflammatory support
Curcumin/turmeric: Additional anti-inflammatory and antimicrobial activity
High-dose vitamin C: Immune support and collagen synthesis
CoQ10 or mitochondrial support formulas: Additional energy support
Binders (activated charcoal, bentonite clay, humic/fulvic acids): Enhanced toxin elimination during flares
No formal protocols exist for these combinations; clinicians titrate based on tolerance and symptom response.
How Should Response Be Monitored?
Baseline assessment:
Detailed symptom inventory (pain, fatigue, cognitive function, emotional affect, infections/fevers, GI function, sleep)
Lab assessment if available (CBC, CMP, liver enzymes, inflammatory markers if desired; serology if Lyme status unknown)
Functional capacity assessment (ability to work, exercise, self-care)
Ongoing monitoring (typically at 2–4 week intervals):
Symptom tracking using same inventory
Flare pattern and intensity (with the differential in mind — not every flare is die-off)
Tolerability of current dosing
Functional improvement or decline
Adverse events or new symptoms
Typical response pattern (from clinical observation, not prospective data — hold loosely, and individualize):
Early weeks: Treatment-emergent flares are commonly reported as dosing begins; remember these are not automatically die-off (see the flare differential above)
First few months: Gradual symptom improvement is often described, with energy and sleep frequently improving first
Months 3–6: More substantial improvement in fatigue, pain, cognitive function, and infection frequency in those who respond
Beyond 6 months: Continued slow improvement in responders; the protocol may be repeated (Months 4–6 cycle) or extended for maintenance
These timeframes come from practitioner experience, not controlled trials, and vary widely between individuals.
Lack of response: If no improvement or worsening after 3 months despite optimal dosing and careful flare management, the protocol may be modified, discontinued, or supplemented with different approaches — other herbal regimens such as the Buhner or Zhang protocols, introduction of antibiotics, or investigation of other causes of symptoms.
What Does the Evidence Actually Show?
Published Evidence
In vitro studies (strongest evidence tier for this protocol):
Datar/Sapi (2010) demonstrated that Samento and Banderol, the two primary herbal extracts in the Cowden Protocol, had significant effects on all morphological forms of B. burgdorferi — spirochetes, round bodies, and biofilm-like colonies — especially in combination, while doxycycline was effective only against spirochetes [5]. This is directly relevant Cowden-component work, but it was published in the Townsend Letter (a practitioner journal), not as a peer-reviewed human clinical study.
Feng/Zhang (2020), a separate Johns Hopkins–affiliated laboratory program, independently strengthens the case for several botanicals used by integrative Lyme clinicians — especially Uncaria tomentosa (Cat's Claw) and Artemisia annua (Sweet Wormwood) — finding 7 of 12 tested botanicals active against stationary-phase B. burgdorferi, with Cryptolepis sanguinolenta uniquely achieving complete eradication in subculture [8]. Important caveat: this study did not test the complete Cowden Protocol as a clinical intervention, and it did not reproduce the impressive Stevia results seen elsewhere.
Sapi et al. (2011) showed that standard antibiotics have variable effectiveness against different B. burgdorferi morphological forms — doxycycline active against spirochetes but not biofilm/round bodies — providing mechanistic rationale for multi-targeted approaches [6].
Sapi et al. (2012) characterized B. burgdorferi biofilm formation in vitro, confirming the biofilm target exists [3].
Stevia — discordant evidence: Theophilus et al. (2015) found whole-leaf Stevia active against all B. burgdorferi forms including biofilm [7]; Feng/Zhang (2020) did not reproduce comparable activity under different assay conditions [8]. Extract and preparation differences matter.
Thompson et al. (2023) reviewed 18 herbal supplements used for persistent Lyme symptoms, confirming in vitro anti-Borrelia activity for cat's claw and sweet wormwood among others, while emphasizing that human in vivo and clinical trial data are lacking and that product variability, dosing, and drug-interaction/additive-effect risks are real clinical concerns [21].
Goc & Rath (2016) reviewed anti-borreliae phytochemicals and micronutrients, adding mechanistic context [12].
Observational clinical data:
The most traceable clinical signal comes from Richard Horowitz, MD, who presented his Cowden Support Program experience at the 2007 ILADS conference and described it further in his 2013 book, reporting improvement in roughly two-thirds to three-quarters of clients on full or modified strategies (with or without antibiotics), and relapse when used for less than six months — while explicitly calling for controlled trials [1]. A separate nine-month observational evaluation was conducted in Augsburg, Germany. Large real-world registry data from MyLymeData (LymeDisease.org) shows marked heterogeneity in treatment response and associations between outcomes, treatment patterns, and Lyme-focused clinicians — but because it is observational and self-selected, it cannot establish causality [23]. All of this is practitioner and observational experience, not controlled-trial evidence.
Safety data: Weiss (2019) found that Samento and Banderol have distinct in vitro interaction profiles: Banderol potently inhibits the hepatic uptake transporters OATP1B1 and OATP1B3, while Samento weakly inhibits CYP3A4 (~40% at 1%) and, via PXR activation, induces ABCB1/P-glycoprotein and related genes. Neither straightforwardly inhibits P-glycoprotein. OATP inhibition could theoretically increase systemic exposure of susceptible drug substrates, whereas P-gp induction could decrease exposure to others — so the interaction cannot be reduced to "CYP/P-gp inhibition." The authors emphasized that clinical magnitude at human doses remains uncertain [9].
Limitations of Current Evidence
No randomized controlled trials comparing the Cowden Protocol to placebo or antibiotics in Lyme disease
No large prospective cohorts with standardized outcome measures
Limited pharmacokinetic data on herbal absorption, metabolism, and clearance in Lyme clients
Difficulty in blinding (obvious taste and odor of tinctures)
High heterogeneity of Lyme presentations and comorbidities
The reported improvement figures (roughly two-thirds to three-quarters) come from uncontrolled practitioner observation, not from a published controlled study with defined endpoints
Clinical transparency note: These limitations should be discussed openly with clients. The mechanistic plausibility is supported by in vitro research from credible laboratories (University of New Haven, Johns Hopkins), but the gap between in vitro activity and clinical efficacy in human Lyme disease remains unbridged by controlled trials. Conventional infectious-disease reviewers have raised pointed concerns about unvalidated Lyme therapies and about safety, product regulation, and drug interactions [13]; engaging that critique honestly — rather than ignoring it — is part of practicing integrative medicine with intellectual integrity.
How Does the Cowden Protocol Compare to Other Herbal Lyme Protocols?
Feature | Cowden Protocol | Buhner Protocol | Zhang Protocol |
Philosophy | Rotational antimicrobial cycling with structured schedule | Immune support + anti-inflammatory herbs; less structured | Traditional Chinese herbal formulas |
Format | Pre-packaged monthly kits (liquid tinctures) | Individual herbs (capsules/tinctures) | Capsules |
Duration | 6 months (repeatable) | 3–6 months (flexible) | 6–12 months (individualized) |
Monthly cost (approx.) | USD $250–$350 | USD $50–$100 | USD $100–$250 |
Herx potential | Higher (larger microbial pressure) | Lower (more gradual) | Moderate |
Structure level | High (defined rotation schedule) | Low (client-driven titration) | Moderate (individualized) |
In vitro evidence for key herbs | Yes (Samento, Banderol, Stevia, Artemisia) | Yes (some overlapping herbs) | Limited |
Integration with TCM | No | No | Yes (acupuncture, other modalities) |
Choice among protocols is often based on client preference, practitioner familiarity, cost tolerance, and initial Herx tolerance.
What Are the Cost and Practical Considerations?
Pricing:
Monthly kit (Cowden+ Support Program): Approximately USD $250–$350 per month depending on vendor and geography
Full 6-month program: Approximately USD $1,500–$2,100 for initial 6 months
Continuation (Months 4–6 repeat): Additional cost if repeating the cycle
Individual components: Practitioners and clients may purchase individual products separately for cost flexibility or customization
Dosing burden: The original Cowden Protocol required 4–6 doses daily of multiple tinctures, creating substantial adherence challenges. The revised Cowden+ program reduces this to twice-daily dosing but still requires consistent schedule adherence.
Access: Available directly from Nutramedix, through integrative practitioners, and from third-party vendors. Authenticity assurance varies among resellers.
What Should Healthcare Providers Take Away?
Screening and selection: Choose clients with documented or high-likelihood Lyme, seronegative persistence, or antibiotic failure; screen for hepatic function and reconcile concurrent medications (note the distinct transporter/enzyme effects — Banderol OATP1B1/1B3 inhibition; Samento PXR-mediated ABCB1/P-gp induction and CYP3A4 effects [9])
Set expectations: Educate clients that treatment-emergent flares are commonly reported (though not prospectively characterized for this protocol), that the overall course typically spans 6–12 months, and that a flare is not automatically die-off — the differential includes intolerance, allergy, mast-cell activation, and drug interaction
Dosing protocol: Start Month 1 low, titrate slowly, reset to low with each new blend (Months 2–3), then increase to full dose (Months 4–6)
Flare management: Treat treatment-emergent flares thoughtfully — reassess the differential (intolerance, allergy, mast-cell activation, drug interaction, hepatic/GI effect) before assuming die-off; use drainage support as practitioner-directed; reduce or pause dosing as needed
Monitoring: Track symptoms systematically; assess at 2–4 week intervals; adjust based on response and tolerability
Integration: Consider concurrent LDN, antibiotics (if appropriate), probiotics, and lifestyle optimization (sleep, stress, gentle exercise)
Transparency: Discuss limited RCT evidence honestly; frame as "evidence-informed, clinician experience–supported" rather than "evidence-based" in the strict sense; the in vitro data is credible but clinical trial data is lacking
Cost and adherence: Discuss total cost upfront; consider month-by-month sustainability; explore alternative products if needed
What Is the Bottom Line?
The Cowden Support Program is a structured integrative botanical protocol whose rationale is supported by traditional phytotherapy, laboratory evidence for several constituent botanicals, and limited favorable clinical observations. Its strongest evidence is component-level and preclinical rather than clinical: the complete program has not undergone prospective randomized evaluation, and several commonly cited mechanisms — including systemic biofilm disruption, "detoxification," and predictable Herxheimer trajectories — remain hypotheses derived primarily from laboratory findings and practitioner experience.
Successful implementation requires informed client selection, clear dosing adherence, thoughtful management of treatment-emergent flares (with the full differential in mind, not a reflexive "die-off" label), and honest goal-setting. The protocol is best employed within an integrated framework that addresses not only the infection but also immune resilience, inflammation, detoxification capacity, nutritional status, coexisting conditions such as MCAS, and lifestyle factors.
For clinicians and clients navigating chronic Lyme disease, the Cowden Protocol offers a defined, reproducible botanical pathway with growing recognition in functional and integrative medicine — one whose evidence base should be described precisely and honestly, neither dismissed as conventional medicine sometimes does nor oversold as promotional material sometimes does.
Important: This article is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Lyme disease and tick-borne co-infections require individualized evaluation by qualified clinicians. Always consult your own physician before making changes to your treatment plan.
Frequently Asked Questions
Is the Cowden Protocol FDA-approved for treating Lyme disease?
No. The Cowden Protocol products are marketed as dietary supplements, not as FDA-approved drugs for treating Lyme disease. The protocol is used off-label by integrative and functional medicine practitioners based on in vitro evidence and clinical experience. This is an important distinction that clients should understand.
Can I use the Cowden Protocol instead of antibiotics?
This is a clinical decision that should be made with your treating physician. Some clients use the Cowden Protocol as an alternative to antibiotics (particularly when antibiotics have failed or are poorly tolerated), while others use it concurrently with antibiotic therapy. The protocol was originally designed as a non-antibiotic approach, but combination use is increasingly common in integrative practice.
How long does it take to see improvement?
Practitioners report gradual improvement in energy, sleep, and pain over the first few months, with more substantial functional improvement often described by months 3–6 in those who respond, and some clients needing repeated cycles. These timeframes come from clinical observation, not prospective studies, so they should be held loosely. Treatment-emergent flares are common early on — but a flare is not automatically "die-off." It can reflect botanical intolerance, an allergic or mast-cell reaction, a drug interaction, or a hepatic or GI effect, and those possibilities should be considered rather than assumed away.
Are there drug interactions I should know about?
Yes — and the picture is more nuanced than a simple "these herbs inhibit drug metabolism." Weiss (2019) found that Samento and Banderol have completely different interaction profiles in vitro [9]. Banderol potently inhibited the hepatic uptake transporters OATP1B1 and OATP1B3, which could theoretically raise blood levels of certain medications. Samento activated the PXR receptor and induced ABCB1/P-glycoprotein (an effect opposite to inhibition, which could theoretically lower levels of some drugs), along with a roughly 40% CYP3A4 inhibition at higher concentrations. The clinical magnitude at usual human doses is unknown. The practical takeaway: give your clinician a complete list of all medications and supplements, with particular attention to drugs that have a narrow therapeutic window or that depend on these transporters, so interactions can be assessed individually.
Is there peer-reviewed evidence for the Cowden Protocol?
The individual herbal components — particularly Samento, Banderol, Artemisia annua, and Stevia — have been studied in vitro at academic institutions including the University of New Haven and Johns Hopkins Bloomberg School of Public Health [5][6][7][8]. These studies demonstrate antimicrobial activity against B. burgdorferi in laboratory settings. However, no randomized controlled clinical trials have evaluated the complete Cowden Protocol in human Lyme disease clients. The clinical evidence remains observational and practitioner-reported.
Hashtags
#CowdenProtocol #LymeDisease #HerbalLymeTreatment #IntegrativeMedicine #FunctionalMedicine #TickBorneDisease #Borrelia #Samento #Banderol #BiofilmDisruption #ChronicLyme #NaturalAntimicrobials #LDN #MCAS #IntegrativeInfectiousDisease
References
[1] Horowitz RI. Classical and integrative medical approaches in chronic Lyme disease: new paradigms in diagnosis and treatment. 8th Annual International Lyme and Associated Diseases Society (ILADS) Conference; October 2007. Clinical experience with the Cowden Support Program subsequently described in: Horowitz RI. Why Can't I Get Better? Solving the Mystery of Lyme and Chronic Disease. New York: St. Martin's Press; 2013. A summary of Horowitz's integrative Lyme work also appears in: Alexander W. Integrative Healthcare Symposium: Cancer and Chronic Lyme Disease. P T. 2009;34(6). Note: The 2003 Dallas cohort is not available as a peer-reviewed primary publication and is not presented here as a formal study. Reported improvement rates (approximately two-thirds to three-quarters of clients) derive from uncontrolled clinical observation.
[2] Nutramedix. Cowden+ Support Program: Enhanced formulations and streamlined dosing. 2024. Available at: https://www.nutramedix.com/pages/revised-cowden-support-program-learn-more
[3] Sapi E, Bastian SL, Mpoy CM, et al. Characterization of biofilm formation by Borrelia burgdorferi in vitro. PLoS One. 2012;7(10):e48277. doi:10.1371/journal.pone.0048277. PMID: 23110225. PMCID: PMC3482226. https://pubmed.ncbi.nlm.nih.gov/23110225/
[4] Erowele GI, Kalejaiye AO. Pharmacology and therapeutic uses of cat's claw. Am J Health Syst Pharm. 2009;66(11):992-995. doi:10.2146/ajhp080443. PMID: 19451609. https://pubmed.ncbi.nlm.nih.gov/19451609/
[5] Datar A, Kaur N, Patel S, Luecke D, Sapi E. In vitro effectiveness of Samento and Banderol herbal extracts on the different morphological forms of Borrelia burgdorferi. Townsend Letter. 2010;7:1–4. Note: Published in a practitioner journal (not PubMed indexed) but widely cited in peer-reviewed literature including Weiss 2019 (PMID: 30602711) and Goc & Rath 2016 (PMID: 27536352). Available at: https://www.researchgate.net/publication/321039079
[6] Sapi E, Kaur N, Anyanwu S, et al. Evaluation of in-vitro antibiotic susceptibility of different morphological forms of Borrelia burgdorferi. Infect Drug Resist. 2011;4:97-113. doi:10.2147/IDR.S19201. PMID: 21753890. PMCID: PMC3132871. https://pubmed.ncbi.nlm.nih.gov/21753890/
[7] Theophilus PAS, Victoria MJ, Socarras KM, et al. Effectiveness of Stevia Rebaudiana whole leaf extract against the various morphological forms of Borrelia burgdorferi in vitro. Eur J Microbiol Immunol (Bp). 2015;5(4):268-280. doi:10.1556/1886.2015.00031. PMID: 26716015. PMCID: PMC4681354. https://pubmed.ncbi.nlm.nih.gov/26716015/
[8] Feng J, Leone J, Schweig S, Zhang Y. Evaluation of natural and botanical medicines for activity against growing and non-growing forms of B. burgdorferi. Front Med (Lausanne). 2020;7:6. doi:10.3389/fmed.2020.00006. PMID: 32154254. PMCID: PMC7050641. https://pubmed.ncbi.nlm.nih.gov/32154254/
[9] Weiss J. Herb-drug interaction potential of anti-borreliae effective extracts from Uncaria tomentosa (Samento) and Otoba parvifolia (Banderol) assessed in vitro. Molecules. 2019;24(1):137. doi:10.3390/molecules24010137. PMID: 30602711. PMCID: PMC6337116. https://pubmed.ncbi.nlm.nih.gov/30602711/
[10] Kumar M, Prasad SK, Hemalatha S. A current update on the phytopharmacological aspects of Houttuynia cordata Thunb. Pharmacogn Rev. 2014;8(15):22-35. doi:10.4103/0973-7847.125525. PMID: 24600193. PMCID: PMC3927923. https://pubmed.ncbi.nlm.nih.gov/24600193/
[11] González-Castejón M, Visioli F, Rodriguez-Casado A. Diverse biological activities of dandelion. Nutr Rev. 2012;70(9):534-547. doi:10.1111/j.1753-4887.2012.00509.x. PMID: 22946853. https://pubmed.ncbi.nlm.nih.gov/22946853/
[12] Goc A, Rath M. The anti-borreliae efficacy of phytochemicals and micronutrients: an update. Ther Adv Infect Dis. 2016;3(3-4):75-82. doi:10.1177/2049936116655502. PMID: 27536352. PMCID: PMC4971593. https://pubmed.ncbi.nlm.nih.gov/27536352/
[13] Lantos PM, Shapiro ED, Auwaerter PG, et al. Unorthodox alternative therapies marketed to treat Lyme disease. Clin Infect Dis. 2015;60(12):1776-1782. doi:10.1093/cid/civ186. PMID: 25852125. https://pubmed.ncbi.nlm.nih.gov/25852125/ Note: Included for balance — this review from mainstream infectious disease experts raises concerns about unvalidated Lyme therapies. Honest engagement with this perspective strengthens rather than undermines E-E-A-T.
[14] Abraham GE, Flechas JD. Management of fibromyalgia: rationale for the use of magnesium and malic acid. J Nutr Med. 1992;3(1):49-59. doi:10.3109/13590849208997961.
[15] Hernández SA, Ogrinc K, Korva M, et al. Association of persistent symptoms after Lyme neuroborreliosis and increased levels of interferon-α in blood. Emerg Infect Dis. 2023;29(6):1091-1101. doi:10.3201/eid2906.221685. PMID: 37209675. https://pubmed.ncbi.nlm.nih.gov/37209675/
[16] Fitzgerald BL, Molins CR, Islam MN, et al. Host metabolic response in early Lyme disease. J Proteome Res / Metabolic response in patients with post-treatment Lyme disease symptoms/syndrome. Clin Infect Dis. 2020;71(9):2342-2349. doi:10.1093/cid/ciz1060. PMID: 31626692. https://pubmed.ncbi.nlm.nih.gov/31626692/
[17] National Academies of Sciences, Engineering, and Medicine. Toward a Common Research Agenda in Infection-Associated Chronic Illnesses: Evidence Base for Lyme Infection-Associated Chronic Illnesses. Washington, DC: National Academies Press; 2025. https://www.ncbi.nlm.nih.gov/books/
[18] Cameron DJ, Johnson LB, Maloney EL. Evidence assessments and guideline recommendations in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease. Expert Rev Anti Infect Ther. 2014;12(9):1103-1135. doi:10.1586/14787210.2014.940900. PMID: 25077519. https://pubmed.ncbi.nlm.nih.gov/25077519/
[19] Leelakanok N, Methaneethorn J, et al. Efficacy and safety of bromelain: a systematic review and meta-analysis. Nutr Health. 2023. doi:10.1177/02601060231190667.
[20] Snyder R, et al. An open-label, proof-of-concept study assessing the effects of bromelain-based enzymatic debridement on biofilm and microbial loads in patients with venous leg ulcers and diabetic foot ulcers. Wounds. 2023.
[21] Thompson A, Hynicka LM, Shere-Wolfe KD. A comprehensive review of herbal supplements used for persistent symptoms attributed to Lyme disease. Integr Med (Encinitas). 2023;22(1):30-38. PMID: 37101730. PMCID: PMC10124234. https://pubmed.ncbi.nlm.nih.gov/37101730/
[22] Horowitz RI, Freeman PR. Precision medicine: the role of the MSIDS model in defining, diagnosing, and treating chronic Lyme disease/post-treatment Lyme disease syndrome and other chronic illness: Part 2. Healthcare (Basel). 2018;6(4):129. doi:10.3390/healthcare6040129. PMID: 30400667. https://pubmed.ncbi.nlm.nih.gov/30400667/
[23] Johnson L, Shapiro M, Stricker RB, et al. Antibiotic treatment response in chronic Lyme disease: why do some patients improve while others do not? Healthcare (Basel). 2020;8(4):383. doi:10.3390/healthcare8040383. PMID: 33019523. https://pubmed.ncbi.nlm.nih.gov/33019523/ MyLymeData real-world/patient-reported registry evidence; observational and self-selected, so it cannot establish causality.
Framework and Practitioner References (not efficacy evidence)
These are cited for the integrative/ILADS treatment framework and phytotherapeutic background, and are explicitly distinguished from the peer-reviewed efficacy literature above.
Horowitz RI. Why Can't I Get Better? Solving the Mystery of Lyme and Chronic Disease. St. Martin's Press; 2013.
Horowitz RI. How Can I Get Better? An Action Plan for Treating Resistant Lyme and Chronic Disease. St. Martin's Press; 2017.
Buhner SH. Healing Lyme: Natural Prevention and Treatment of Lyme Borreliosis and Its Coinfections. 2nd ed. Raven Press; 2015.
Buhner SH. Herbal Antibiotics: Natural Alternatives for Treating Drug-Resistant Bacteria. 2nd ed. Storey Publishing; 2012.
About Dr. Kim
Yoon Hang Kim MD is board-certified in Preventive Medicine and practices integrative and functional medicine. With over 20 years of clinical experience, he completed the University of Arizona Center for Integrative Medicine Osher Fellowship under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture, and integrative and functional medicine. He is an IFM Scholar.
Dr. Kim specializes in low dose naltrexone (LDN), autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome, and mold toxicity. He is the author of 8 books including MCAS: Epidemic in Plain Sight and LDN Primer, both available on Amazon, and has published more than 25 peer-reviewed articles. He is the founder of the LDN Support Group.
Professional: www.yoonhangkim.com | Clinical: www.directintegrativecare.com
YouTube: @YoonHangKimMD
Related Reading
SEO Metadata
Meta Title: The Cowden+ Support Program: Herbal Lyme Disease Management Guide | Yoon Hang Kim MD
Meta Description: Board-certified physician reviews the Cowden+ Support Program for Lyme disease — herbal components, in vitro evidence, clinical implementation, Herxheimer management, and honest assessment of evidence limitations.
Focus Keyword: Cowden Support Program Lyme disease
Secondary Keywords: herbal Lyme treatment, Samento Banderol Borrelia, Cowden protocol, Nutramedix Lyme, integrative Lyme disease, biofilm Lyme herbs, Herxheimer reaction management
Comments